Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. - Wikidata - awgldk - TriplyDB

Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors.

Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors.

http://www.wikidata.org/entity/Q33402226

about

Multidisciplinary management of nonfunctional neuroendocrine tumor of the pancreas Medical management of brain tumors and the sequelae of treatment.Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids Advances in small bowel neuroendocrine neoplasia New therapeutic approaches to metastatic gastroenteropancreatic neuroendocrine tumors: A glimpse into the future.A nanoparticle carrying the p53 gene targets tumors including cancer stem cells, sensitizes glioblastoma to chemotherapy and improves survival.Bevacizumab-based combination therapy for advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a systematic review of the literature.Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.Biologics in gastrointestinal and pancreatic neuroendocrine tumors Outcomes of patients treated with capecitabine and temozolamide for advanced pancreatic neuroendocrine tumors (PNETs) and non-PNETs Expression of O(6)-methylguanine DNA methyltransferase (MGMT) and its clinical significance in gastroenteropancreatic neuroendocrine neoplasm A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor.Impact of prior chemotherapy use on the efficacy of everolimus in patients with advanced pancreatic neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-3 trial.Appropriateness of systemic treatments in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors.O6-Methylguanine-DNA methyltransferase status in neuroendocrine tumours: prognostic relevance and association with response to alkylating agents Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors.Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study.Endocrine vasculatures are preferable targets of an antitumor ineffective low dose of anti-VEGF therapy The Role of Capecitabine/Temozolomide in Metastatic Neuroendocrine Tumors.Update on management of midgut neuroendocrine tumors.A phase II study of axitinib in advanced neuroendocrine tumors.Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours Emerging therapies and latest development in the treatment of unresectable pancreatic neuroendocrine tumors: an update for clinicians.Advances in the Treatment of Pancreatic Neuroendocrine Tumors (pNETs).The PARP inhibitor ABT-888 potentiates dacarbazine-induced cell death in carcinoids.Systemic chemotherapy with FOLFOX in metastatic grade 1/2 neuroendocrine cancer Clinicopathological, treatment, and prognosis study of 43 gastric neuroendocrine carcinomas.Safety and efficacy of sunitinib in patients with unresectable pancreatic neuroendocrine tumors.Treatment of multiple endocrine neoplasia 1/2 tumors: case report and review of the literature.Novel molecular targets for the treatment of gastroenteropancreatic endocrine tumors: answers and unsolved problems Sunitinib malate for the treatment of pancreas malignancies--where does it fit?Neuroendocrine neoplasms of the GI tract: the role of cytotoxic chemotherapy.Management of advanced and/or metastatic carcinoid tumors: historical perspectives and emerging therapies.Evolving treatment strategies for management of carcinoid tumors.The interplay between the immune system and chemotherapy: emerging methods for optimizing therapy.Molecular biology of neuroendocrine tumors: from pathways to biomarkers and targets.Pancreatic NETs: where do we stand now?Zirconium-89 labeled antibodies: a new tool for molecular imaging in cancer patients.Vascular endothelial growth factor (VEGF) pathway and neuroendocrine neoplasms (NENs): prognostic and therapeutic considerations.Molecular pathogenesis and targeted therapy of sporadic pancreatic neuroendocrine tumors.

P2860

Q26752757-126DED24-8609-4EED-B09B-925B0FE09855 Q26992174-BE96D0DA-C703-4B6F-904B-EDD7B1BC9B2C Q26996521-8D524E53-2DD7-4282-B89F-4D7C4B5C5941 Q27000397-2C71633C-91E5-451C-9D1C-6E4B4D57C2DB Q30364864-ACCC3CFC-D0FD-44EA-BA51-5040EE5CA3B5 Q30412393-E98A46F1-AFD7-46CC-94AD-3AAA09C693DC Q31170918-8214F160-7362-4B4B-B48E-C8EA78858753 Q33405625-A5861A66-DAC2-43F6-9075-1E995B5444C2 Q33895557-BA777F53-F67B-46D7-B2A0-5456716ABBAC Q33948026-61EFFBD5-881F-450E-AFF8-3D46BC6D264E Q34029197-223B41D3-03B5-4D07-A5A9-33FC9E7CDC85 Q35020652-6E95D5CC-F598-4D4A-841E-F0D6A9A82882 Q35081993-3AF87127-CBCA-41D6-B5AB-FC773DECA64B Q35128224-C79CAF31-225B-4BE2-BF9C-7089EAF848DD Q35677887-4D4EBE6A-3082-47EC-8C16-9FB0910102BF Q35738251-D36FA0AE-8273-49A0-A196-AC9C2564A643 Q36708349-87AAD639-67D9-4E5E-9226-38A8CD659F3A Q36821570-9C497A40-CAB9-49C5-8D0B-975DC1E61FF4 Q37017037-4F7CDEA7-97E6-41ED-8DA5-A6FE64D18162 Q37025143-7A38ECAB-63A7-4033-99DE-6F255FD80268 Q37131421-9DB1C62C-DB2F-4DD2-98D8-208F49FB9A09 Q37182210-FCF652D4-0279-44D9-BD31-FCC064FD4362 Q37255846-4BA8F60A-F732-451E-93B7-342CAC690B4B Q37362261-84B20A35-A96B-472C-B576-2DD69C0F89E2 Q37372483-F4A6FAFB-F3EE-4E47-B3EB-77F1AFDE4A40 Q37594074-17705B15-D99E-4779-A4CC-B230164B53B7 Q37624511-7443DBBF-0BCC-4112-BC0E-9BE84802E1A2 Q38066186-5CD7F06D-B6B9-41C4-B8C4-0DBA1500AC2E Q38067034-E12D0933-6209-4268-95FD-4F1BF28233D8 Q38076275-B2358D87-6B53-406C-8418-43BFD144C1E2 Q38086310-6A17A02F-F5C3-484E-8D93-23CE2BC90DA8 Q38096476-650E1B4A-5334-4566-AA0B-804F179C7197 Q38112804-72F2BD57-13AE-432D-BDBB-48637F463FA1 Q38124702-6D93487B-B042-47D0-8678-2B487781D621 Q38168953-21719880-88A5-4F7C-AC17-FA9AB4BF0DD8 Q38174516-98E1353D-6CF0-4D14-BED2-C77C8BE23739 Q38181004-3FD764AB-0F22-4080-81CD-DFA539D95A7C Q38225877-979EB6B9-414D-4827-AEA7-71E2827B1D84 Q38250467-F8FD35E6-004A-4045-BAB4-AE2799FDE1AC Q38331666-78E36814-9C51-492E-B73F-9531315A069B

P2860

Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors.

http://www.wikidata.org/entity/Q33402226

description

2012 nî lūn-bûn

@nan

2012 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Prospective study of bevacizum ...... dvanced neuroendocrine tumors.

@ast

Prospective study of bevacizum ...... dvanced neuroendocrine tumors.

@en

type

label

Prospective study of bevacizum ...... dvanced neuroendocrine tumors.

@ast

Prospective study of bevacizum ...... dvanced neuroendocrine tumors.

@en

prefLabel

Prospective study of bevacizum ...... dvanced neuroendocrine tumors.

@ast

Prospective study of bevacizum ...... dvanced neuroendocrine tumors.

@en

P1433

Q33402226-714D5AE3-3736-4833-B4BE-54E6EE900FCA

P1476

Q33402226-16A9CB39-9B4E-4351-B9DF-F2B1A0664CFC

P2093

Q33402226-3B6A0E18-D4EF-4E9C-A57E-FF38B2D48CB1

Q33402226-73EAF645-9F94-4304-877A-888E58C3D94E

Q33402226-9D69B481-CCA2-4B99-8D53-97B332D416AF

Q33402226-A54B75DA-4DB4-47B9-A971-2BE9DD819668

Q33402226-ACEF453A-61F6-4DA2-A743-4857AAA3FA9C

Q33402226-AEFE4837-9FB8-4EC9-B487-040C5F5F0E39

Q33402226-C8B67CC0-E5E0-412D-9BF5-AF1CFBA78BF1

Q33402226-E33ACF20-DB3A-448A-A8DA-D03FD4396124

Q33402226-F5297CB3-2755-47E5-BE15-B77BE54C3913

P2860

Q33402226-188DEC77-5201-4FD6-ABAB-733E9288D20B

Q33402226-192C2C12-2483-4933-958A-E7652FDF7F1A

Q33402226-1B3060B5-6E5C-497B-A191-11D024059133

Q33402226-1C46C496-F71D-406D-8487-20C410616BEA

Q33402226-33D34CB0-A8F5-4828-8013-CBC448E8F848

Q33402226-3CF8EC21-05D3-4442-94AF-F08899DB97AB

Q33402226-4BC0C178-0B4C-479F-B6C8-2626673E7CA6

Q33402226-4DD14863-2FCC-469F-807B-0C5613126F32

Q33402226-97C12FC8-75AD-4949-A745-971E330D5190

Q33402226-9B115952-2F89-44FC-884F-55CD78B46D53

P304

Q33402226-77D680EB-9107-4F13-AD72-BA0D4AEB0A44

P31

Q33402226-BF28BD06-EC97-442E-98BF-536CC47C8F6E

P356

Q33402226-E41AA9B8-71CF-4237-87D6-8CA4F49C690F

P407

Q33402226-E566D972-D762-4DB0-B2B6-E4A692732AE2

P433

Q33402226-D90A42DD-2866-4D02-AA72-7AE89F43FF04

P478

Q33402226-9704B37F-CC16-4589-9FA6-0CD0ED20922D

P50

Q33402226-144BC88C-5D1B-424F-A479-A321A217DB87

Q33402226-88BD33B4-9E30-4C95-B73B-614A38431CC1

Q33402226-C21D8C8E-B93B-43E2-B4F5-E609C238898A

P577

Q33402226-BC838552-DF8F-47FC-96F7-27A32AD8DC8D

P5875

Q33402226-21111C53-5431-43F5-82F0-85877DCAD0E0

P698

Q33402226-A0BB61F0-8B86-490F-8FB9-ABC6A8899D2D

P921

Q33402226-5F594E91-B51D-452A-B378-5DED4C9665DA

P932

Q33402226-4390649D-9CB9-45AE-8160-CE33AF180B75

P356

JCO.2011.40.3147

P1433

Journal of Clinical Oncology

P1476

Prospective study of bevacizum ...... dvanced neuroendocrine tumors.

@en

P2093

Craig C Earle

http://www.w3.org/2001/XMLSchema#string

Hui Zheng

http://www.w3.org/2001/XMLSchema#string

Jeffrey W Clark

http://www.w3.org/2001/XMLSchema#string

Jennifer A Chan

http://www.w3.org/2001/XMLSchema#string

Keith Stuart

http://www.w3.org/2001/XMLSchema#string

Lawrence Blaszkowsky

http://www.w3.org/2001/XMLSchema#string

Matthew H Kulke

http://www.w3.org/2001/XMLSchema#string

Pankaj Bhargava

http://www.w3.org/2001/XMLSchema#string

Peter C Enzinger

http://www.w3.org/2001/XMLSchema#string

P2860

Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors.

Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome.

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

Everolimus for advanced pancreatic neuroendocrine tumors.

Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme.

O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors.

First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.

A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors.

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.

Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282.

P304

2963-2968

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2011.40.3147

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P50

Charles S. Fuchs

Jeffrey A Meyerhardt

P577

2012-07-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

229016064

http://www.w3.org/2001/XMLSchema#string

P698

22778320

http://www.w3.org/2001/XMLSchema#string

P921

P932

4874232

http://www.w3.org/2001/XMLSchema#string